Lixisenatide added to basal insulin reduces glycaemic variability in patients with type 2 diabetes mellitus

"Background and aims: This analysis evaluated the impact on glycaemic variability (GV) of lixisenatide (LIXI) vs placebo (PBO) as add-on to basal insulin ± oral antidiabetes drugs (OADs) in patients with type 2 diabetes mellitus (T2DM). Materials and methods: Patient-level data from GetGoal-L,...

Descripción completa

Detalles Bibliográficos
Autores Principales: O‘Neal, D., Umpierrez, G., DiGenio, A., Goldenberg, R., Hernandez-Triana, E., Lin, J., Park, C.-Y., Renard, E., Kovatchev, B.
Formato: Objeto de conferencia (Conference Object)
Lenguaje:Inglés (English)
Publicado: Springer Nature 2014
Acceso en línea: